Daiichi Sankyo And Ranbaxy To Launch Hypertension Drug Olmesartan In India
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Daiichi Sankyo announced March 31 the launch of hypertension treatment Olmetec (olmesartan) in India through Indian subsidiary Ranbaxy Laboratories. Olmetec is Daiichi's best-selling drug and the company aims to utilize Ranbaxy's extensive sales force and know-how in India. Ranbaxy will market it as Olvance starting in April. (Click here for more - Japanese language